Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Zepbound"

22 News Found

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen
News | April 14, 2026

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen

GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access


Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option
News | March 17, 2026

Lilly expands access to Zepbound weight-loss drug with $299 monthly self-pay option

The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect


FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
Drug Approval | February 24, 2026

FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment

In 2025, over 1 million patients accessed Lilly treatments through LillyDirect


Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity
R&D | January 09, 2026

Breakthrough in PsA: Taltz plus Zepbound show major gains for patients with obesity

This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures


Lilly slashes prices on Zepbound vials to expanding access to obesity treatment
News | December 02, 2025

Lilly slashes prices on Zepbound vials to expanding access to obesity treatment

Patients can now get the starting 2.5 mg dose for $299 per month


LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound
Supply Chain | October 30, 2025

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound

Walmart, with nearly 4,600 pharmacies nationwide, will serve as the first in-store pickup pharmacy for LillyDirect's self-pay single-dose vials


Zepbound is now available in US for adults living with obesity
News | December 09, 2023

Zepbound is now available in US for adults living with obesity

Express Scripts to add Zepbound to National Preferred Formulary


Eli Lilly unveils $4.5 bn Indiana expansion
News | May 07, 2026

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies


Lilly posts explosive Q1 2026 results
News | May 04, 2026

Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates


Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData
Biopharma | April 03, 2026

Q2 2026 drug catalysts put Replimune, Arvinas and Boehringer in sharp focus: GlobalData

Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning